Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07398417 · ClinicalTrials.gov registry record · Phase 3
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
A Phase 3 study of Fibromyalgia, sponsored by Axsome Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 620
- Enrollment target
- 16
- Study locations
NCT07398417: Recruiting Phase 3 study of Fibromyalgia, sponsored by Axsome Therapeutics.
NCT07398417 is a Phase 3 study of Fibromyalgia that is actively recruiting participants, run by Axsome Therapeutics. The registered enrollment target is 620 participants, above the 171-participant average among 76 other Fibromyalgia trials with a reported enrollment target (263% higher). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07398417, a Phase 3 study of Fibromyalgia, is actively recruiting participants, sponsored by Axsome Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 620 participants
- Enrollment target
- 16
- Study locations
Study Summary
The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AXS-14 (Esreboxetine)
Study Locations (16)
Florida
- Clinical Research Site - Jacksonville
- Clinical Research Site - Orlando
- Clinical Research Site - Tampa
Missouri
- Clinical Research Site - Springfield
- Clinical Research Site - Town and Country
Arkansas
- Clinical Research Site - Little Rock
California
- Clinical Research Site - Santa Ana
Connecticut
- Clinical Research Site - Cromwell
Georgia
- Clinical Research Site - Atlanta
Kansas
- Clinical Research Site - Overland Park
Kentucky
- Clinical Research Site - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2028-03 |
| Phase | Phase 3 |
What NCT07398417 shows while recruiting
NCT07398417 is an interventional study that assigns participants to a tested intervention. The registered 620 participants enrollment target is mid-sized for trials with a published cap, above the 171-participant average among 76 other Fibromyalgia trials with a reported enrollment target (263% higher).
The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07398417 lists 16 locations in 13 states (Florida, Missouri, Arkansas).
Frequently Asked Questions
What is clinical trial NCT07398417 about?
NCT07398417 is a clinical study titled "Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design". The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.
What is the current status of trial NCT07398417?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2026-01-14. Estimated completion is 2028-03.
What conditions does trial NCT07398417 study?
This clinical trial studies the following conditions: Fibromyalgia.
What interventions are being tested in trial NCT07398417?
The interventions under investigation include: Placebo (DRUG), AXS-14 (Esreboxetine) (DRUG).
Who is sponsoring clinical trial NCT07398417?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07398417 being conducted?
This trial has 16 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07398417's enrollment target sits among peer trials
620 4th of 76 higher than 73 of 76 other Fibromyalgia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study
COMPLETED · Phase 3
-
Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia
COMPLETED · Phase 3
-
Fibromyalgia TENS in Physical Therapy Study (TIPS): an Embedded Pragmatic Clinical Trial
COMPLETED · Phase 3
-
Study of Milnacipran for the Treatment of Fibromyalgia
COMPLETED · Phase 3
-
Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia
COMPLETED · Phase 3
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
- NCT05822466 · 620 participants · NA
Virtual Tai ji Quan Exercise to Prevent Falls in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI